BioMarin Pharmaceutical (BMRN) Reiterated at Overweight by Cantor Fitzgerald After Webinar
Tweet Send to a Friend
Cantor Fitzgerald analyst Olivia Brayer reiterated an Overweight rating and $85.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
